Triple
T5999473
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | Novo Nordisk North American headquarters |
E133557
|
entity |
| Predicate | regulatesOrCoordinates |
P65374
|
FINISHED |
| Object |
Novo Nordisk North American diabetes-care operations
Novo Nordisk North American diabetes-care operations comprise the regional business unit responsible for developing, marketing, and supporting the company’s diabetes treatments and related services across North America.
|
E133557
|
NE FINISHED |
How this triple was built (4 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: Novo Nordisk North American diabetes-care operations | Statement: [Novo Nordisk North American headquarters, regulatesOrCoordinates, Novo Nordisk North American diabetes-care operations]
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Novo Nordisk North American diabetes-care operations Context triple: [Novo Nordisk North American headquarters, regulatesOrCoordinates, Novo Nordisk North American diabetes-care operations]
-
A.
Novo Nordisk North American headquarters
Novo Nordisk North American headquarters is the main regional corporate office of the global healthcare company Novo Nordisk, overseeing its pharmaceutical and diabetes-care operations across North America.
-
B.
Novo Nordisk
Novo Nordisk is a global healthcare company based in Denmark, best known as a leading producer of insulin and other diabetes care treatments.
-
C.
The Treatment of Diabetes Mellitus
"The Treatment of Diabetes Mellitus" is a landmark medical textbook by Elliott P. Joslin that helped establish modern clinical approaches to diagnosing and managing diabetes.
-
D.
Joslin Diabetes Center
Joslin Diabetes Center is a world-renowned medical and research institution specializing in diabetes care, education, and scientific investigation.
-
E.
Diabetic Manual for the Mutual Use of Doctor and Patient
Diabetic Manual for the Mutual Use of Doctor and Patient is an early, influential guide to diabetes care written by pioneering American diabetologist Elliott P. Joslin to help physicians and patients manage the disease collaboratively.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NEDg
Description generation
gpt-5.1
Instruction
Generate a one-sentence description of the target entity. You are given a context triple in the form (subject, predicate, object), where the object is the target entity. # Instructions Use the triple to infer relevant information about the entity. Describe the entity based on what is most defining, well-known. Avoid repeating the information from the triple, unless really essential. # Response Format Return only the sentence: "Description: [one-sentence description of the target entity]"
Input
Entity: Novo Nordisk North American diabetes-care operations Triple: [Novo Nordisk North American headquarters, regulatesOrCoordinates, Novo Nordisk North American diabetes-care operations]
Generated description
Novo Nordisk North American diabetes-care operations comprise the regional business unit responsible for developing, marketing, and supporting the company’s diabetes treatments and related services across North America.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: Novo Nordisk North American diabetes-care operations Target entity description: Novo Nordisk North American diabetes-care operations comprise the regional business unit responsible for developing, marketing, and supporting the company’s diabetes treatments and related services across North America.
-
A.
Novo Nordisk North American headquarters
chosen
Novo Nordisk North American headquarters is the main regional corporate office of the global healthcare company Novo Nordisk, overseeing its pharmaceutical and diabetes-care operations across North America.
-
B.
Novo Nordisk
Novo Nordisk is a global healthcare company based in Denmark, best known as a leading producer of insulin and other diabetes care treatments.
-
C.
The Treatment of Diabetes Mellitus
"The Treatment of Diabetes Mellitus" is a landmark medical textbook by Elliott P. Joslin that helped establish modern clinical approaches to diagnosing and managing diabetes.
-
D.
Joslin Diabetes Center
Joslin Diabetes Center is a world-renowned medical and research institution specializing in diabetes care, education, and scientific investigation.
-
E.
Diabetic Manual for the Mutual Use of Doctor and Patient
Diabetic Manual for the Mutual Use of Doctor and Patient is an early, influential guide to diabetes care written by pioneering American diabetologist Elliott P. Joslin to help physicians and patients manage the disease collaboratively.
- F. None of above.
Provenance (5 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69c00870ddbc81909880fa3864f4f38d |
completed | March 22, 2026, 3:19 p.m. |
| NER | Named-entity recognition | batch_69c0560bae148190ad4755defaaf471b |
completed | March 22, 2026, 8:50 p.m. |
| NED1 | Entity disambiguation (via context triple) | batch_69c1087d08f081909842940a28bddb35 |
completed | March 23, 2026, 9:31 a.m. |
| NEDg | Description generation | batch_69c1094d6d408190abde0d2e582c15a5 |
completed | March 23, 2026, 9:35 a.m. |
| NED2 | Entity disambiguation (via description) | batch_69c109c333208190b90911e0cab58377 |
completed | March 23, 2026, 9:37 a.m. |
Created at: March 22, 2026, 4:05 p.m.